Equine performance genes and the future of doping in horseracing.

A horse's success on the racetrack is determined by genetics, training and nutrition, and their translation into physical traits such as speed, endurance and muscle strength. Advances in genetic technologies are slowly explaining the roles of specific genes in equine performance, and offering new insights into the development of novel therapies for diseases and musculoskeletal injuries that cause early retirement of many racehorses. Gene therapy approaches may also soon provide new means to artificially enhance the physical performance of racehorses. Gene doping, the misuse of gene therapies for performance enhancement, is predicted to be the next phase of doping faced by horseracing. The risk of gene doping to human sports has been recognised for almost 15 years, and the introduction of the first gene doping detection tests for doping control in human athletes is imminent. Gene doping is also a threat to horseracing, but there are currently no methods to detect it. Efficient and accurate detection methods need to be developed to deter those looking to use gene doping in horses and to maintain the integrity of the sport. Methods developed for human athletes could offer an avenue for detection in racehorses. Development of an equine equivalent test will first require identification of equine genes that will likely be targeted by gene doping attempts. This review focuses on genes that have been linked to athletic performance in horses and, therefore, could be targeted for genetic manipulation. The risks associated with gene doping and approaches to detect gene doping are also discussed. Copyright © 2017 John Wiley & Sons, Ltd.

[1]  F. Giordano,et al.  Gene-based therapeutic angiogenesis. , 2003, Seminars in thoracic and cardiovascular surgery.

[2]  H. Birch,et al.  A review of tendon injury: why is the equine superficial digital flexor tendon most at risk? , 2010, Equine veterinary journal.

[3]  A. Hahn,et al.  Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise , 2002, European Journal of Applied Physiology.

[4]  J. Zierath,et al.  Exercise metabolism and the molecular regulation of skeletal muscle adaptation. , 2013, Cell metabolism.

[5]  C. Bustamante,et al.  A Mutation in the Myostatin Gene Increases Muscle Mass and Enhances Racing Performance in Heterozygote Dogs , 2007, PLoS genetics.

[6]  P. Houweling,et al.  Sequence analysis of the equine ACTN3 gene in Australian horse breeds. , 2014, Gene.

[7]  M. Déry,et al.  Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. , 2005, The international journal of biochemistry & cell biology.

[8]  S. Ohno,et al.  Genetically directed preferential X-activation seen in mice , 1974 .

[9]  M. Thevis,et al.  Emerging drugs: mechanism of action, mass spectrometry and doping control analysis. , 2009, Journal of mass spectrometry : JMS.

[10]  O. Distl,et al.  Candidate genes for physical performance in the horse. , 2011, The Veterinary Journal.

[11]  N. Kara,et al.  PPAR-α and PPARGC1A gene variants have strong effects on aerobic performance of Turkish elite endurance athletes , 2014, Molecular Biology Reports.

[12]  K. Ho,et al.  Growth hormone and physical performance , 2011, Trends in Endocrinology & Metabolism.

[13]  Eugene Muchnik,et al.  HIF prolyl hydroxylase inhibitors for anemia , 2011, Expert opinion on investigational drugs.

[14]  M. Thevis,et al.  Identification of fibroblast growth factor 1 (FGF-1) in a black market product. , 2011, Drug testing and analysis.

[15]  P. Teale,et al.  Impact of the emergence of designer drugs upon sports doping testing , 2009 .

[16]  B. Kieffer,et al.  Opiates: basic mechanisms , 2006 .

[17]  L. Chandler,et al.  Delivery of FGF genes to wound repair cells enhances arteriogenesis and myogenesis in skeletal muscle. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  R. Shephard,et al.  The Cytokine Response to Physical Activity and Training , 2001, Sports medicine.

[19]  C. Lundby,et al.  Time for change: a roadmap to guide the implementation of the World Anti-Doping Code 2015 , 2014, British Journal of Sports Medicine.

[20]  D. Popov,et al.  PPARα gene variation and physical performance in Russian athletes , 2006, European Journal of Applied Physiology.

[21]  E. Hill,et al.  Characterization of the equine skeletal muscle transcriptome identifies novel functional responses to exercise training , 2010, BMC Genomics.

[22]  E. Hill,et al.  Targets of selection in the Thoroughbred genome contain exercise-relevant gene SNPs associated with elite racecourse performance. , 2010, Animal genetics.

[23]  C. Kahn,et al.  A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. , 1998, Molecular cell.

[24]  T. Wan,et al.  Doping control analyses in horseracing: a clinician's guide. , 2014, The Veterinary Journal.

[25]  B. Langley,et al.  Myostatin Inhibits Myoblast Differentiation by Down-regulating MyoD Expression* , 2002, The Journal of Biological Chemistry.

[26]  Ramakant Gupta,et al.  FIBROBLAST GROWTH FACTOR (FGF): A REVIEW , 2013 .

[27]  I. Ahmetov,et al.  Effect of HIF1A gene polymorphism on human muscle performance , 2008, Bulletin of Experimental Biology and Medicine.

[28]  James M. Wilson,et al.  Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies. , 2015, Human gene therapy methods.

[29]  D. MacArthur,et al.  Genes and human elite athletic performance , 2005, Human Genetics.

[30]  M. Haskins,et al.  Large animal models and gene therapy , 2006, European Journal of Human Genetics.

[31]  J. Bertram,et al.  Insulin‐like growth factor‐I improves cellular and molecular aspects of healing in a collagenase‐induced model of flexor tendinitis , 2002, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[32]  N. Orr,et al.  A Sequence Polymorphism in MSTN Predicts Sprinting Ability and Racing Stamina in Thoroughbred Horses , 2010, PloS one.

[33]  E. Barrey Reviewe: Genetics and genomics in equine exercise physiology: an overview of the new applications of molecular biology as positive and negative markers of performance and health. , 2010, Equine veterinary journal. Supplement.

[34]  E. Barton,et al.  Viral expression of insulin-like growth factor-I isoforms promotes different responses in skeletal muscle. , 2006, Journal of applied physiology.

[35]  E. G. Cothran,et al.  Genetic Diversity in the Modern Horse Illustrated from Genome-Wide SNP Data , 2013, PloS one.

[36]  L. Tentori,et al.  Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? , 2007, Pharmacological research.

[37]  Zhen Yan,et al.  Regulation of exercise-induced fiber type transformation, mitochondrial biogenesis, and angiogenesis in skeletal muscle. , 2011, Journal of applied physiology.

[38]  Shahram Mohaghegh,et al.  Doping and the Latest Prohibited List of the World Anti-Doping Agency (WADA) , 2013 .

[39]  Anupama Koneru,et al.  Endogenous Opioids: Their Physiological Role and Receptors , 2009 .

[40]  J. Segura,et al.  Recombinant Erythropoietin and Analogues: A Challenge for Doping Control , 2004, Therapeutic drug monitoring.

[41]  J. Grieger,et al.  scAAVIL-1ra dosing trial in a large animal model and validation of long-term expression with repeat administration for osteoarthritis therapy , 2015, Gene Therapy.

[42]  R. Geor,et al.  Insulin resistance in equids: possible role in laminitis. , 2006, The Journal of nutrition.

[43]  S. Robertson,et al.  Pain control in horses: what do we really know? , 2014, Equine veterinary journal.

[44]  A. Musarò,et al.  Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Paul D Robbins,et al.  IL-1ra/IGF-1 Gene Therapy Modulates Repair of Microfractured Chondral Defects , 2007, Clinical orthopaedics and related research.

[46]  D. Wells,et al.  Gene doping: the hype and the reality , 2008, British journal of pharmacology.

[47]  John Gleaves Enhancing the Odds: Horse Racing, Gambling and the First Anti-Doping Movement in Sport, 1889–1911 , 2012 .

[48]  M. Audran,et al.  Detection of recombinant epoetin and darbepoetin alpha after subcutaneous administration in the horse. , 2005, Journal of analytical toxicology.

[49]  J. Adamson,et al.  Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. , 1987, The New England journal of medicine.

[50]  E. Hill,et al.  Sequence variants at the myostatin gene locus influence the body composition of Thoroughbred horses. , 2011, The Journal of veterinary medical science.

[51]  Nobuyuki Itoh,et al.  Fibroblast growth factors , 2001, Genome Biology.

[52]  J. Mendell,et al.  Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates , 2009, Science Translational Medicine.

[53]  Wilhelm Schänzer,et al.  Insulins in equine urine: qualitative analysis by immunoaffinity purification and liquid chromatography/tandem mass spectrometry for doping control purposes in horse-racing. , 2008, Rapid communications in mass spectrometry : RCM.

[54]  J. Glorioso,et al.  Gene therapy for the treatment of chronic peripheral nervous system pain , 2012, Neurobiology of Disease.

[55]  E. Hill,et al.  MSTN genotypes in Thoroughbred horses influence skeletal muscle gene expression and racetrack performance. , 2012, Animal genetics.

[56]  B. Essén-Gustavsson,et al.  Energy metabolism in relation to skeletal muscle fibre properties during treadmill exercise. , 1985, Equine veterinary journal.

[57]  F. Bushman,et al.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.

[58]  Yi Zhang,et al.  Erythropoietin gene therapy leads to autoimmune anemia in macaques. , 2004, Blood.

[59]  Nicole SanGiacomo The Impact of Myostatin Genetic Polymorphism on Muscle Conformation in the Horse , 2013 .

[60]  J. Gibney,et al.  The Growth Hormone/Insulin-Like Growth Factor-I Axis in Exercise and Sport. , 2007, Endocrine reviews.

[61]  Y. Meckel,et al.  NRF2 intron 3 A/G polymorphism is associated with endurance athletes' status. , 2009, Journal of applied physiology.

[62]  A. Abu-Seida Regenerative Therapy for Equine Osteoarthritis: A Concise Review , 2015 .

[63]  A. Thiruvenkadan,et al.  Inheritance of racing performance of Thoroughbred horses , 2009 .

[64]  D. Clemmons,et al.  Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.

[65]  C. Gabay,et al.  Genetics: Mutations in the IL1RN locus lead to autoinflammation , 2009, Nature Reviews Rheumatology.

[66]  V. Erspamer,et al.  PHARMACOLOGICAL DATA ON DERMORPHINS, A NEW CLASS OF POTENT OPIOID PEPTIDES FROM AMPHIBIAN SKIN , 1981, British journal of pharmacology.

[67]  Dirk Moser,et al.  Establishment of two quantitative nested qPCR assays targeting the human EPO transgene , 2016, Gene Therapy.

[68]  F. Sato,et al.  Nucleotide sequence of equine erythropoietin and characterization of region-specific antibodies. , 2004, American journal of veterinary research.

[69]  Scott M. Williams,et al.  Variable number of tandem repeat polymorphisms of the interleukin-1 receptor antagonist gene IL-1RN: a novel association with the athlete status , 2010, BMC Medical Genetics.

[70]  R. Geor,et al.  Chapter 1.1 – The horse as an athlete: a physiological overview , 2008 .

[71]  A. Beineke,et al.  Effect of a single injection of autologous conditioned serum (ACS) on tendon healing in equine naturally occurring tendinopathies , 2015, Stem Cell Research & Therapy.

[72]  G. Gaffney,et al.  Gene doping: a review of performance-enhancing genetics. , 2007, Pediatric clinics of North America.

[73]  A. Nieß,et al.  Direct and long-term detection of gene doping in conventional blood samples , 2011, Gene Therapy.

[74]  K. Lindblad-Toh,et al.  A Deletion in the Canine POMC Gene Is Associated with Weight and Appetite in Obesity-Prone Labrador Retriever Dogs , 2016, Cell metabolism.

[75]  A. Baoutina,et al.  Improved detection of transgene and nonviral vectors in blood. , 2013, Human gene therapy methods.

[76]  C. McIlwraith,et al.  Therapeutic use of stem cells in horses: which type, how, and when? , 2013, Veterinary journal.

[77]  N. Orr,et al.  Correction: A Sequence Polymorphism in MSTN Predicts Sprinting Ability and Racing Stamina in Thoroughbred Horses , 2010, PLoS ONE.

[78]  A. Ducasse,et al.  Genomic structure, polymorphism and expression of the horse alpha-actinin-3 gene. , 2012, Gene.

[79]  F. Piras,et al.  Genome-wide evolutionary and functional analysis of the Equine Repetitive Element 1: an insertion in the myostatin promoter affects gene expression , 2015, BMC Genetics.

[80]  N. Robinson,et al.  Detection of EPO doping and blood doping: the haematological module of the Athlete Biological Passport. , 2012, Drug testing and analysis.

[81]  Eric Meadows,et al.  A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[82]  B. Hamilton,et al.  Growth factor delivery methods in the management of sports injuries: the state of play , 2007, British Journal of Sports Medicine.

[83]  Kwan Hee Lee,et al.  Cell mediated gene therapy: A guide for doctors in the clinic , 2015 .

[84]  Iain Watt,et al.  Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: radiologic assessment. , 2001, Seminars in arthritis and rheumatism.

[85]  Mai M H Mansour,et al.  Gene doping: of mice and men. , 2009, Clinical biochemistry.

[86]  J. Mendell,et al.  Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors , 2008, Proceedings of the National Academy of Sciences.

[87]  E. Howley,et al.  Criteria for maximal oxygen uptake: review and commentary. , 1995, Medicine and science in sports and exercise.

[88]  H-T Huang,et al.  Electroporation-mediated pain-killer gene therapy for mononeuropathic rats , 2002, Gene Therapy.

[89]  H. Sweeney,et al.  Viral expression of insulin-like growth factor-I enhances muscle hypertrophy in resistance-trained rats. , 2004, Journal of applied physiology.

[90]  L. W. Greene,et al.  Physiologic and skeletal response to exogenous equine somatotropin (eST) in two-year-old Quarter Horses in race training , 1998 .

[91]  M. Giacca,et al.  Transgene Detection by Digital Droplet PCR , 2014, PloS one.

[92]  M. Weitzman,et al.  Gene therapy: twenty-first century medicine. , 2005, Annual review of biochemistry.

[93]  J. Vine,et al.  The detection of a synthetic Interleukin-1 receptor antagonist peptide in a seized product from a racing stable. , 2016, Drug Testing and Analysis.

[94]  T. Wallimann Bioenergetics: Dissecting the role of creatine kinase , 1994, Current Biology.

[95]  A. Solinger,et al.  Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. , 2005, Arthritis and rheumatism.

[96]  R. Verlengia,et al.  Myostatin: genetic variants, therapy and gene doping , 2012 .

[97]  Maria M. Mihaylova,et al.  AMPK and PPARδ Agonists Are Exercise Mimetics , 2008, Cell.

[98]  Momiao Xiong,et al.  Investigation gene and microRNA expression in glioblastoma , 2009, 2009 International Joint Conference on Bioinformatics, Systems Biology and Intelligent Computing.

[99]  Florian Caiment,et al.  A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep , 2006, Nature Genetics.

[100]  I. Alexander,et al.  Synthetic certified DNA reference material for analysis of human erythropoietin transgene and transcript in gene doping and gene therapy , 2016, Gene Therapy.

[101]  B. Swanepoel,et al.  Growth hormone abuse in the horse: preliminary assessment of a mass spectrometric procedure for IGF-1 identification and quantitation. , 2001, Rapid communications in mass spectrometry : RCM.

[102]  J. Bartlett,et al.  Inflammation and Immune Response of Intra-Articular Serotype 2 Adeno-Associated Virus or Adenovirus Vectors in a Large Animal Model , 2012, Arthritis.

[103]  T. Noakes Tainted glory--doping and athletic performance. , 2004, The New England journal of medicine.

[104]  K. Graham,et al.  The Effects of Growth Hormone on Body Composition and Physical Performance in Recreational Athletes , 2010, Annals of Internal Medicine.

[105]  M. Gerard,et al.  Effects of somatotropin and training on indices of exercise capacity in Standardbreds. , 2010, Equine veterinary journal. Supplement.

[106]  C. Kawcak,et al.  Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. , 2007, American journal of veterinary research.

[107]  J. Wood,et al.  Factors associated with failure of thoroughbred horses to train and race. , 2010, Equine veterinary journal.

[108]  T. Braun,et al.  Myostatin mutation associated with gross muscle hypertrophy in a child. , 2004, The New England journal of medicine.

[109]  Hung-Chih Kuo,et al.  Loss of non-coding RNA expression from the DLK1-DIO3 imprinted locus correlates with reduced neural differentiation potential in human embryonic stem cell lines , 2015, Stem Cell Research & Therapy.

[110]  G. Lippi,et al.  Telmisartan as metabolic modulator: a new perspective in sports doping? , 2012, Journal of strength and conditioning research.

[111]  E. P. Cunningham,et al.  Estimation of genetic trend in racing performance of thoroughbred horses , 1988, Nature.

[112]  I. Macdougall,et al.  Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. , 2009, Advances in chronic kidney disease.

[113]  S. Nakae,et al.  Development of Chronic Inflammatory Arthropathy Resembling Rheumatoid Arthritis in Interleukin 1 Receptor Antagonist–Deficient Mice , 2000, The Journal of experimental medicine.

[114]  D. MacArthur,et al.  ACTN3 genotype is associated with human elite athletic performance. , 2003, American journal of human genetics.

[115]  Se-Jin Lee,et al.  Suppression of body fat accumulation in myostatin-deficient mice. , 2002, The Journal of clinical investigation.

[116]  F. Booth,et al.  Molecular and cellular adaptation of muscle in response to exercise: perspectives of various models. , 1991, Physiological reviews.

[117]  E. Hill,et al.  Association of sequence variants in CKM (creatine kinase, muscle) and COX4I2 (cytochrome c oxidase, subunit 4, isoform 2) genes with racing performance in Thoroughbred horses. , 2010, Equine veterinary journal. Supplement.

[118]  J. Isner,et al.  Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. , 1995, Circulation.

[119]  D. MacArthur,et al.  ACTN3 genotype influences muscle performance through the regulation of calcineurin signaling. , 2013, The Journal of clinical investigation.

[120]  C F Kearns,et al.  Overview of horse body composition and muscle architecture: implications for performance. , 2002, Veterinary journal.

[121]  G. S. Bains,et al.  Gene doping detection: evaluation of approach for direct detection of gene transfer using erythropoietin as a model system , 2010, Gene Therapy.

[122]  Y. Meckel,et al.  Is the interaction between HIF1A P582S and ACTN3 R577X determinant for power/sprint performance? , 2010, Metabolism: clinical and experimental.

[123]  R. Samulski,et al.  Autoimmune anemia in macaques following erythropoietin gene therapy. , 2004, Blood.

[124]  Jos W. M. van der Meer,et al.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases , 2012, Nature Reviews Drug Discovery.

[125]  J. Rivero A scientific background for skeletal muscle conditioning in equine practice. , 2007, Journal of veterinary medicine. A, Physiology, pathology, clinical medicine.

[126]  M. Flück Functional, structural and molecular plasticity of mammalian skeletal muscle in response to exercise stimuli , 2006, Journal of Experimental Biology.

[127]  E. P. Cunningham,et al.  Genetics of performance traits. , 2000 .

[128]  E. Park,et al.  Regulation of pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression by glucocorticoids and insulin , 2010, Molecular and Cellular Endocrinology.

[129]  L. J. McCutcheon,et al.  Effects of dexamethasone on glucose dynamics and insulin sensitivity in healthy horses. , 2007, American journal of veterinary research.

[130]  J. N. MacLeod,et al.  Genome Sequence, Comparative Analysis, and Population Genetics of the Domestic Horse , 2009, Science.

[131]  G. Ferraz,et al.  Polymorphisms in MCT1, CD147, PDK4, and DMRT3 genes in Arabian and Quarter Horses , 2017 .

[132]  H Fessi,et al.  Gene therapy and DNA delivery systems. , 2014, International journal of pharmaceutics.

[133]  K. McKeever,et al.  Low dose exogenous erythropoietin elicits an ergogenic effect in standardbred horses. , 2006, Equine veterinary journal. Supplement.

[134]  Mai M H Mansour,et al.  Doping in the recombinant era: strategies and counterstrategies. , 2005, Clinical biochemistry.

[135]  T. Collares,et al.  The use of genes for performance enhancement: doping or therapy? , 2011, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[136]  D. Glass IGF-1 Regulation of Skeletal Muscle Hypertrophy and Atrophy , 2010 .

[137]  S. Mosler,et al.  Modulation of Follistatin and Myostatin Propeptide by Anabolic Steroids and Gender , 2013, International Journal of Sports Medicine.

[138]  A. Schambach,et al.  Gene therapy on the move , 2013, EMBO molecular medicine.

[139]  L. Ellegård,et al.  Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes. , 2005, The Journal of clinical endocrinology and metabolism.

[140]  E. Hill,et al.  Horses for courses: a DNA-based test for race distance aptitude in thoroughbred racehorses. , 2012, Recent patents on DNA & gene sequences.

[141]  Benjamin Stich,et al.  Genome-wide association mapping of iron homeostasis in the maize association population , 2015, BMC Genetics.

[142]  J. Wilson,et al.  Delivery and evaluation of recombinant adeno‐associated viral vectors in the equine distal extremity for the treatment of laminitis , 2017, Equine veterinary journal.

[143]  D. McMiken An energetic basis of equine performance. , 1983, Equine veterinary journal.

[144]  F. Gage,et al.  Retrovirus‐Mediated Expression of an Artificial β‐Endorphin Precursor in Primary Fibroblasts , 1995, Journal of neurochemistry.

[145]  P. R. van Weeren,et al.  Effects of platelet‐rich plasma on the quality of repair of mechanically induced core lesions in equine superficial digital flexor tendons: A placebo‐controlled experimental study , 2009, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[146]  C. Velloso Regulation of muscle mass by growth hormone and IGF‐I , 2008, British journal of pharmacology.

[147]  C. Bouchard,et al.  Muscle genetic variants and relationship with performance and trainability. , 1989, Medicine and science in sports and exercise.

[148]  James Goss,et al.  Gene therapy for pain: Results of a phase I clinical trial , 2011, Annals of neurology.

[149]  T. Witte,et al.  Intralesional injection of insulin-like growth factor-I for treatment of superficial digital flexor tendonitis in Thoroughbred racehorses: 40 cases (2000-2004). , 2011, Journal of the American Veterinary Medical Association.

[150]  Peter Olson,et al.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0288 Minireview: Lipid Metabolism, Metabolic Diseases, and , 2022 .

[151]  A. Russell,et al.  Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle. , 2003, Diabetes.

[152]  L. Manchon,et al.  Blood cells RNA biomarkers as a first long-term detection strategy for EPO abuse in horseracing. , 2010, Drug testing and analysis.

[153]  Stuart Egginton,et al.  Invited review: activity-induced angiogenesis , 2009, Pflügers Archiv - European Journal of Physiology.

[154]  F. Parsa,et al.  Avoiding Opioids and Their Harmful Side Effects in the Postoperative Patient: Exogenous Opioids, Endogenous Endorphins, Wellness, Mood, and Their Relation to Postoperative Pain. , 2016, Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health.

[155]  M. Anshel,et al.  Effect of aerobic and strength training on pain tolerance, pain appraisal and mood of unfit males as a function of pain location. , 1994, Journal of sports sciences.

[156]  E. Birks,et al.  LC−MS/MS Method for Confirmation of Recombinant Human Erythropoietin and Darbepoetin α in Equine Plasma , 2007 .

[157]  Martial Saugy,et al.  The athlete biological passport. , 2011, Clinical chemistry.

[158]  Robert A. Harris,et al.  Role of Pyruvate Dehydrogenase Kinase 4 in Regulation of Blood Glucose Levels , 2010, Korean diabetes journal.

[159]  M. Bidlingmaier,et al.  Doping with Growth Hormone , 2001, Journal of pediatric endocrinology & metabolism : JPEM.

[160]  C. McIlwraith,et al.  Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene , 2002, Gene Therapy.

[161]  L. Regitano,et al.  Comparison of Sequence Variants in the PDK4 and COX4I2 Genes Between Racing and Cutting Lines of Quarter Horses and Associations With the Speed Index , 2016 .

[162]  L. Douglass,et al.  expression and , 2006 .

[163]  F. Bressolle,et al.  Pharmacokinetics and haematological parameters of recombinant human erythropoietin after subcutaneous administrations in horses. , 1996, Biopharmaceutics & drug disposition.

[164]  Adam Bagg,et al.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.

[165]  Kerry R Emslie,et al.  Developing strategies for detection of gene doping , 2008, The journal of gene medicine.

[166]  M. Rivera,et al.  Role of Creatine Kinase Isoenzymes on Muscular and Cardiorespiratory Endurance , 2001, Sports medicine.

[167]  H. Lee,et al.  Molecular Characterization and Expression Analysis of the Peroxisome Proliferator Activated Receptor Delta (PPARδ) Gene before and after Exercise in Horse , 2015, Asian-Australasian journal of animal sciences.

[168]  S. Welle,et al.  Inventory of high-abundance mRNAs in skeletal muscle of normal men. , 1999, Genome research.

[169]  E. Hill,et al.  PGC-1α encoded by the PPARGC1A gene regulates oxidative energy metabolism in equine skeletal muscle during exercise. , 2012, Animal genetics.

[170]  J. Tidball Inflammatory processes in muscle injury and repair. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[171]  A. Mobasheri,et al.  Cobalt chloride doping in racehorses: Concerns over a potentially lethal practice. , 2015, Veterinary journal.

[172]  K. Maiese,et al.  Angiogenesis and plasticity: role of erythropoietin in vascular systems. , 2002, Journal of hematotherapy & stem cell research.

[173]  Se-Jin Lee,et al.  Double muscling in cattle due to mutations in the myostatin gene. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[174]  E. Hill,et al.  Alterations in oxidative gene expression in equine skeletal muscle following exercise and training. , 2010, Physiological genomics.

[175]  A. Pokrywka,et al.  GENES IN SPORT AND DOPING , 2013, Biology of sport.

[176]  A. Jamurtas,et al.  β-Endorphin Response to Exercise , 1997 .

[177]  Se-Jin Lee,et al.  Regulation of myostatin activity and muscle growth , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[178]  I. Alexander,et al.  Potential use of gene transfer in athletic performance enhancement. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[179]  B. Le Bizec,et al.  Identification of recombinant equine growth hormone in horse plasma by LC-MS/MS: a confirmatory analysis in doping control. , 2008, Analytical chemistry.

[180]  G. Semenza,et al.  HIF-1 Regulates Cytochrome Oxidase Subunits to Optimize Efficiency of Respiration in Hypoxic Cells , 2007, Cell.

[181]  Theodore Friedmann,et al.  Gene doping in sports: the science and ethics of genetically modified athletes. , 2011, Advances in genetics.

[182]  Seungwoo Hwang,et al.  Whole transcriptome analyses of six thoroughbred horses before and after exercise using RNA-Seq , 2012, BMC Genomics.

[183]  T. Gustafsson Vascular remodelling in human skeletal muscle. , 2011, Biochemical Society transactions.

[184]  Peter H. Sönksen,et al.  Insulin, growth hormone and sport. , 2001 .

[185]  Z Domljan,et al.  Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. , 1998, Arthritis and rheumatism.

[186]  Y. Meckel,et al.  Do PPARGC1A and PPARα polymorphisms influence sprint or endurance phenotypes? , 2010, Scandinavian journal of medicine & science in sports.

[187]  J. Fisher,et al.  Erythropoietin: Physiology and Pharmacology Update 2 , 2003, Experimental biology and medicine.

[188]  M. Fedoruk,et al.  Myostatin inhibition: a potential performance enhancement strategy? , 2008, Scandinavian journal of medicine & science in sports.

[189]  E. Hill,et al.  Moderate and high intensity sprint exercise induce differential responses in COX4I2 and PDK4 gene expression in Thoroughbred horse skeletal muscle. , 2010, Equine veterinary journal. Supplement.

[190]  J. Davis,et al.  Role of brain IL-1beta on fatigue after exercise-induced muscle damage. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[191]  Henriette Pilegaard,et al.  Exercise induces transient transcriptional activation of the PGC‐1α gene in human skeletal muscle , 2003, The Journal of physiology.

[192]  T. Wirth,et al.  History of gene therapy. , 2013, Gene.

[193]  D. Bienzle,et al.  Reticulocyte changes after experimental anemia and erythropoietin treatment of horses. , 2005, Journal of applied physiology.

[194]  U. Ekelund,et al.  PPARGC1A genotype (Gly482Ser) predicts exceptional endurance capacity in European men. , 2005, Journal of applied physiology.

[195]  M. Penaud-Budloo,et al.  Longevity of rAAV vector and plasmid DNA in blood after intramuscular injection in nonhuman primates: implications for gene doping , 2011, Gene Therapy.